CLS

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Potential, Visual acuity, Patient, Research, American Medical Association, Targeted drug delivery, Conference, American Academy of Ophthalmology, R, Diabetes, Diabetic retinopathy, Webcast, Literature, American Academy, Administration, DME, G&A, Research and development, Physician, Paratriathlon, Retina, Drug delivery, Pharming, Eye, Intravitreal injection, BioCryst Pharmaceuticals, SCS, Edema, AAO, Melanoma, AURA, Solubility, Partnership, AMD, Clearside, Bausch & Lomb, OASIS, Axitinib, Plasma, Clinical trial, CLS, CPT, Conference call, UME, Injection, HIV disease progression rates, Pharmaceutical industry, Nursing, Video game

ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • Other Income: Other income for the third quarter of 2023 was $0.4 million, compared to $0.2 million for the third quarter of 2022.
  • Other Expense: Non-cash interest expense for the third quarter of 2023 was $2.6 million, compared to $1.3 million in the third quarter of 2022.
  • Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

CLS Americas States KASRAEIAN Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation

Retrieved on: 
Thursday, November 9, 2023
FDA, Erectile dysfunction, CLS, Temperature, FLA, Urology, Physician, Organization, Prostate cancer, FACS, Prostate, Microsoft mobile services, Cancer, Patient, Diagnosis, Urinary incontinence, Medical imaging

LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that KASRAEIAN Urology located in Jacksonville, FL, will begin treating prostate cancer patients using the TRANBERG™ Thermal Therapy System to provide focal laser ablation treatments.

Key Points: 
  • LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that KASRAEIAN Urology located in Jacksonville, FL, will begin treating prostate cancer patients using the TRANBERG™ Thermal Therapy System to provide focal laser ablation treatments.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “We look forward to adding the TRANBERG focal laser ablation treatment option for our low-to-intermediate risk prostate cancer patients.
  • It allows them to gain access to our image-guided TRANBERG focal laser ablation system without any capital equipment expense,” said Michael Magnani, president of CLS Americas.

CLS Americas and HALO Diagnostics Initiate Prostate Cancer Clinical Study using TRANBERG Focal Laser Ablation System

Retrieved on: 
Tuesday, November 7, 2023
Trial of the century, Erectile dysfunction, CLS, ASC, FLA, Urology, Prostate cancer, ED, Quality of life, Risk, HALO, Patient, Diagnosis, Urinary incontinence, Medical imaging

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO Diagnostics , a leader in precision diagnostics and image-guided therapies (HALO Dx), today announced a 25-patient clinical study using the TRANBERG™ Thermal Therapy System to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate cancer in patients.

Key Points: 
  • LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO Diagnostics , a leader in precision diagnostics and image-guided therapies (HALO Dx), today announced a 25-patient clinical study using the TRANBERG™ Thermal Therapy System to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate cancer in patients.
  • The CLS TRANBERG System provides safe and effective focal laser ablation of low-to-medium risk prostate tumors, while also preserving healthy tissue to minimize the risk of unwanted side effects such as ED and urinary incontinence.
  • “CLS is pleased to collaborate with Dr. Scionti and HALO Diagnostics for this clinically significant study regarding the efficacy of treating prostate cancer using image-guided focal laser ablation in an ASC,” stated Michael Magnani, president of CLS Americas.
  • “HALO Diagnostic is excited to begin this clinically significant study with CLS Americas and to begin offering this safe and minimally invasive procedure with the new TRANBERG laser through our network.”

California Life Sciences announces 20th annual Pantheon Award winners

Retrieved on: 
Thursday, November 2, 2023
La Jolla Institute for Immunology, CLS, Avantor, Golden, AbbVie, Immunology, Pantheon, Patient, Westin St. Francis, SAN, Film industry

SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- SAN FRANCISCO, Calif., Nov 2, 2023 -- California Life Sciences (CLS), the state’s most impactful life sciences trade association, today announced the winners of its 20th annual Pantheon Awards.

Key Points: 
  • SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- SAN FRANCISCO, Calif., Nov 2, 2023 -- California Life Sciences (CLS), the state’s most impactful life sciences trade association, today announced the winners of its 20th annual Pantheon Awards.
  • "Congratulations to the winners of the 20th Annual Pantheon Awards,” said Mike Guerra, CLS president & CEO.
  • “They are shining examples of dedication to scientific advancement and innovation, and they inspire us to keep pushing boundaries in pursuit of new solutions for patients around the world.”
    The 2023 Pantheon Award winners, by category, are:
    Erica Ollmann Saphire, Ph.D., La Jolla Institute for Immunology – Academia, Non-Profit, & Research Award
    Pantheon is California’s largest life sciences award celebration that brings together more than 500 industry pioneers each year.
  • After the open nomination period, finalists were chosen by the 2023 Pantheon Advisory Committee, and winners were selected through a public voting campaign which received more than 2,000 votes.

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

Retrieved on: 
Wednesday, November 1, 2023
Axitinib, CLS, AMD, Injection, Pharming, OASIS, Disease, Paratriathlon, Clinical trial, Clearside, Eye, Safety, Patient, Pharmaceutical industry

ALPHARETTA, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the completion of recruitment in its ODYSSEY Phase 2b clinical trial, a randomized, double-masked, parallel-group, active-controlled, multi-center study in participants with neovascular age-related macular degeneration (wet AMD). ODYSSEY is evaluating the safety and efficacy of CLS-AX (axitinib injectable suspension), a highly potent tyrosine kinase inhibitor delivered directly to the site of disease via Clearside’s SCS Microinjector®.

Key Points: 
  • ALPHARETTA, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the completion of recruitment in its ODYSSEY Phase 2b clinical trial, a randomized, double-masked, parallel-group, active-controlled, multi-center study in participants with neovascular age-related macular degeneration (wet AMD).
  • ODYSSEY is evaluating the safety and efficacy of CLS-AX (axitinib injectable suspension), a highly potent tyrosine kinase inhibitor delivered directly to the site of disease via Clearside’s SCS Microinjector®.
  • Following the completion of recruitment, final participants will be randomized to the CLS-AX treatment arm or the aflibercept comparator arm by the middle of December 2023.
  • “The efficacy and safety results from the study will guide the path forward for our pivotal Phase 3 development program for CLS-AX.

CLS Americas Announces Kearney Urology Center will use its TRANBERG Laser to Provide Focal Laser Ablation Treatments to Prostate Cancer Patients

Retrieved on: 
Tuesday, October 24, 2023
FDA, PC, Erectile dysfunction, CLS, Urology, Temperature, FLA, Mobile service, Physician, Prostate cancer, Prostate, Mobile Servicing System, Patient, Diagnosis, Urinary incontinence, Medical imaging

In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.

Key Points: 
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “We are excited to begin offering this new minimally invasive focal laser ablation treatment to our patients with low-to-intermediate risk prostate cancer.
  • The CLS Laser is very precise, easy to operate, and the treatment workflow is similar to prostate cryotherapy procedures,” stated Garrett D. Pohlman, M.D., Kearney Urology Center.
  • “CLS Americas is pleased to provide the Kearney Urology Center, PC with the training, use, and clinical support of our TRANBERG focal laser ablation system,” stated Michael Magnani, president of CLS Americas.

Anti-Drone Market worth $5.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, October 17, 2023
Northrop, Security, Airbus Defence and Space, AE, Sensor, Raytheon Technologies, AeroVironment, Control, CLS, FMS, Detectives Inc., Communication, Evaporated milk, Device, GTRI Electro-Optical Systems Laboratory, Airport, Lockheed Martin, Theiss UAV Solutions, International, Navigation, Altitude, Driverless tractor, Radar, Component, Battelle Memorial Institute, Motion, Hardware, GPS, Radio frequency, Data, Radiation therapy, Jammer, Lidar, Internet, Analytics, Defense, Growth, Precision livestock farming, Grumman, SUAS, Radio, Video game, Instrumentation, Medical imaging, Arms industry, Agriculture, Software, Geography, Region, Boeing

The electronic system segment is expected to capture ~52% of market share in 2028.

Key Points: 
  • The electronic system segment is expected to capture ~52% of market share in 2028.
  • By application: detection and disruption application to account for the largest market share in the forecasted year.
  • The detection and disruption segment accounted for the largest share of ~80% of the anti-drone industry , by application, in 2028.
  • The military and defense vertical are expected to capture ~68% of market share in 2028.

Anti-Drone Market worth $5.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, October 17, 2023
Northrop, Security, Airbus Defence and Space, AE, Sensor, Raytheon Technologies, AeroVironment, Control, CLS, FMS, Detectives Inc., Communication, Evaporated milk, Device, GTRI Electro-Optical Systems Laboratory, Airport, Lockheed Martin, Theiss UAV Solutions, International, Navigation, Altitude, Driverless tractor, Radar, Component, Battelle Memorial Institute, Motion, Hardware, GPS, Radio frequency, Data, Radiation therapy, Jammer, Lidar, Internet, Analytics, Defense, Growth, Precision livestock farming, Grumman, SUAS, Radio, Video game, Instrumentation, Medical imaging, Arms industry, Agriculture, Software, Geography, Region, Boeing

The electronic system segment is expected to capture ~52% of market share in 2028.

Key Points: 
  • The electronic system segment is expected to capture ~52% of market share in 2028.
  • By application: detection and disruption application to account for the largest market share in the forecasted year.
  • The detection and disruption segment accounted for the largest share of ~80% of the anti-drone industry , by application, in 2028.
  • The military and defense vertical are expected to capture ~68% of market share in 2028.

Celestica Launches its Next Generation 800G Switch, Powering Artificial Intelligence and Advancing Data Center Connectivity for the Future 

Retrieved on: 
Monday, October 16, 2023
Cloud, Silicon, NYSE, TSX, Engineering, SJCC, CLS, Sonic, TBPS, OSFP, Software, Head, Open Network Install Environment, OCP, HPS, ONIE, Celestica, Business development, ML, Video game, Broadcom Inc.

The DS5000 switch will be on display at this week’s 2023 OCP Global Summit .

Key Points: 
  • The DS5000 switch will be on display at this week’s 2023 OCP Global Summit .
  • It is the newest addition to Celestica’s Hardware Platform Solutions (HPS) portfolio of cutting-edge storage, compute, networking, and webscale solutions.
  • It features 64 OSFP 800GbE ports, providing a 51.2 Tbps Ethernet-based fabric solution within a 2U form factor to deliver next-generation, high-performance networking.
  • In addition, the DS5000 enables next-gen power efficiency, offering more than 75% power reduction from previous generation 400G switches.

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Retrieved on: 
Monday, October 16, 2023
CLS, CST, Eye, Inflammation, MD, Aes, Toxicity, Axitinib, SCS, Disease, Gene therapy of the human retina, NAMD, AMD, Diabetic retinopathy, Clinical trial, Persistent, Pharming, Patient, Retina, Visual acuity, Injection, Observation, Șaeș, TKI, Pharmaceutical industry

ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial were presented at The Retina Society 56th Annual Scientific Meeting. The results of the trial demonstrate the key benefits of Clearside’s patented suprachoroidal delivery platform and its lead drug candidate, CLS-AX (axitinib injectable suspension) being developed for the treatment of neovascular age-related macular degeneration (wet AMD or nAMD).

Key Points: 
  • ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial were presented at The Retina Society 56th Annual Scientific Meeting.
  • Based on the data from OASIS, CLS-AX is currently being investigated in a Phase 2b clinical trial entitled ODYSSEY.
  • “Our trial is enrolling as planned and we expect data from ODYSSEY in the third quarter of 2024.
  • In the OASIS and Extension Study, participants with wet AMD who were sub-responders with active disease at screening were followed for up to 6 months after CLS-AX treatment.